Topics:

Astra Zeneca and Merck partner on drug regimen

Astra Zeneca and Merck partner on drug regimen

AstraZeneca and Merck & Co. have formed an alliance to research the combination of two investigational compounds: AZD6244 (ARRY-886) from AstraZeneca and MK-2206 from Merck. They will work together on a phase I trial and share the costs of the research.

AZD6244 blocks the MEK pathway and is currently under investigation in skin, colorectal, and lung cancers. MK-2206 is an AKT pathway inhibitor that has shown promise in phase I testing in advanced solid tumors (ASCO 2009 abstract 3503).

 
Loading comments...
Please Wait 20 seconds or click here to close